Skip to main content
. 2021 Aug 4;14(6):1306–1322. doi: 10.1038/s41385-021-00431-5

Fig. 3. Aiolos is induced in non-intestinal ILC2s by IL-33.

Fig. 3

a–c Purified lung ILC2s were treated with indicated cytokines in the presence of IL-7 (10 ng/ml) for 24 h. Concentration for all cytokines were used at 10 ng/ml except for TGF-β (1 ng/ml), TL1A (100 ng/ml) and TSLP (20 ng/ml). a mRNA expression of Ikzf3 was analyzed by Q-PCR. b Expression of Aiolos was analyzed by flow cytometry. c Mean fluorescence intensity (MFI) of Aiolos is shown. d ILC2s from different tissues of wild-type mice were sorted and cultured with IL-7 (10 ng/mL) and IL-33 (10 ng/mL) for 14 days. The expression of Aiolos in IL-33-treated ILC2s compared to freshly isolated ILC2s from indicated organs was analyzed by flow cytometry. e Expression of Aiolos in PBS or IL-33 (intraperitoneal injection of IL-33, 500 ng/day/mouse) treated mice gated on ILC2s from indicated organs was analyzed by flow cytometry. Histogram of Aiolos expression is shown. f Human peripheral blood ILC2s were isolated and treated with indicated cytokines for 5 days. Histogram shows Aiolos expression analyzed by flow cytometry. a, c Error bars are mean ± SEM. d–e BM bone marrow, LI large intestine, SI small intestine, P pancreas, L lung. a–f Data are representative of two to four independent experiments.